| Standardized immunological assays for assessing COVID-19 vaccines by the CEPI-Centralized Laboratory Network A Azizi, D Ogbeni, G Kamuyu, LM Schwartz, C Clark, P Spencer, ... npj Vaccines 9 (1), 128, 2024 | | 2024 |
| Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis M Manak, L Gagnon, S Phay-Tran, P Levesque-Damphousse, A Fabie, ... The Lancet Microbe 5 (3), e216-e225, 2024 | 3 | 2024 |
| Standardization and Harmonization of SARS-COV-2 Assays Offered by the CEPI Centralized Laboratory Network in Support for Vaccine Clinical Trials MM Manak, L Gagnon, S Phay-Tran, P Levesque-Damphousse, A Fabie, ... | | 2023 |
| Histo-blood group antigen null phenotypes associated with a decreased risk of clinical rotavirus vaccine failure among children< 2 years of age participating in the vaccine … LM Schwartz, J Oshinsky, M Reymann, MD Esona, MD Bowen, ... Clinical Infectious Diseases 76 (Supplement_1), S153-S161, 2023 | 2 | 2023 |
| An introduction to the Marburg virus vaccine consortium, MARVAC RW Cross, IM Longini, S Becker, K Bok, D Boucher, MW Carroll, JV Díaz, ... PLoS pathogens 18 (10), e1010805, 2022 | 38 | 2022 |
| Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials JB Braunfeld, HN Carson, SR Williams, LM Schwartz, KM Neuzil, JR Ortiz Vaccine 40 (32), 4339-4347, 2022 | 2 | 2022 |
| Advances and gaps in SARS-CoV-2 infection models. JS Coma PLoS Pathogens 18 (1), 2022 | | 2022 |
| Advances and gaps in SARS-CoV-2 infection models C Muñoz-Fontela, L Widerspick, RA Albrecht, M Beer, MW Carroll, ... PLoS pathogens 18 (1), e1010161, 2022 | 70 | 2022 |
| Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium L Schwartz, A Caixàs, A Dimitropoulos, E Dykens, J Duis, S Einfeld, ... Journal of Neurodevelopmental Disorders 13, 1-13, 2021 | 53 | 2021 |
| Suicidality in individuals with Prader-Willi syndrome: a review of registry survey data A Peleggi, J Bohonowych, TV Strong, L Schwartz, SJ Kim BMC psychiatry 21, 1-9, 2021 | 7 | 2021 |
| Validation of a Pictorial Survey Tool to Measure Time Use in an African Urban Setting LM Schwartz, J Mutanga, R Kakaire, P Davis-Olwell, A Handel, J Sekandi, ... Sociological Methods & Research 50 (3), 1436-1451, 2021 | 1 | 2021 |
| The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control KS Vannice, SL Hills, LM Schwartz, AD Barrett, J Heffelfinger, J Hombach, ... npj Vaccines 6 (1), 82, 2021 | 48 | 2021 |
| Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome N Kayadjanian, C Vrana-Diaz, J Bohonowych, TV Strong, J Morin, ... PLoS One 16 (3), e0248739, 2021 | 24 | 2021 |
| Impact of rotavirus vaccine introduction in children less than 2 years of age presenting for medical care with diarrhea in rural Matlab, Bangladesh LM Schwartz, K Zaman, M Yunus, AH Basunia, ASG Faruque, T Ahmed, ... Clinical Infectious Diseases 69 (12), 2059-2070, 2019 | 11 | 2019 |
| c International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b), Dhaka, Bangladesh d Department of Biostatistics, School of Public Health, University of … LM Schwartz, K Zaman, M Yunusc, AH Basuniac, ASG Faruque, T Ahmed, ... | | 2019 |
| High levels of caregiver burden in Prader-Willi syndrome N Kayadjanian, L Schwartz, E Farrar, KA Comtois, TV Strong PloS one 13 (3), e0194655, 2018 | 83 | 2018 |
| Rotavirus vaccines in low-income settings LM Schwartz | | 2018 |
| EVALUATION OF THE TEST-NEGATIVE CASE-CONTROL DESIGN TO ESTIMATE ROTAVIRUS VACCINE EFFECTIVENESS IN LOW-INCOME SETTINGS LM Schwartz, ME Halloran, A Rowhani-Rahbar, KM Neuzil, JC Victor AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 95 (5), 377-378, 2017 | | 2017 |
| Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design LM Schwartz, ME Halloran, A Rowhani-Rahbar, KM Neuzil, JC Victor Vaccine 35 (1), 184-190, 2017 | 53 | 2017 |
| The dengue vaccine pipeline: Implications for the future of dengue control LM Schwartz, ME Halloran, AP Durbin, IM Longini Jr Vaccine 33 (29), 3293-3298, 2015 | 183 | 2015 |
